Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+™ and Remplir™.
Orthocell has achieved a second consecutive quarter of record revenue, reporting revenue of $2.03m in the September ‘24 Quarter. Revenue is up 7.82% on the $1.88 million achieved in the June ‘24 Quarter, showing clear traction with new and existing surgeons, translating to growing sales of the Company’s market-leading products Striate+™ and Remplir™
Orthocell CEO and MD, Paul Anderson, said:
“We are delighted with the continued growth in demand and record quarterly revenue for our market-leading products Striate+ and Remplir. These sales results demonstrate increasing market traction, which is driven by the consistent and predictable outcomes surgeons can achieve using our products. We are excited by the potential for exponential growth and believe we are on track to become a key player in a US$4 billion global market.”